222 related articles for article (PubMed ID: 11422598)
1. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics.
Willems L; van der Geest R; de Beule K
J Clin Pharm Ther; 2001 Jun; 26(3):159-69. PubMed ID: 11422598
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of itraconazole.
De Beule K; Van Gestel J
Drugs; 2001; 61 Suppl 1():27-37. PubMed ID: 11219548
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations.
Buchanan CM; Buchanan NL; Edgar KJ; Klein S; Little JL; Ramsey MG; Ruble KM; Wacher VJ; Wempe MF
J Pharm Sci; 2007 Nov; 96(11):3100-16. PubMed ID: 17712849
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
[TBL] [Abstract][Full Text] [Related]
5. Making sense of itraconazole pharmacokinetics.
Prentice AG; Glasmacher A
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i17-i22. PubMed ID: 16120630
[TBL] [Abstract][Full Text] [Related]
6. Intravenous itraconazole.
Slain D; Rogers PD; Cleary JD; Chapman SW
Ann Pharmacother; 2001 Jun; 35(6):720-9. PubMed ID: 11408991
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with itraconazole in systemic fungal infections.
Boogaerts M; Maertens J
Drugs; 2001; 61 Suppl 1():39-47. PubMed ID: 11219549
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection.
Zhao Q; Zhou H; Pesco-Koplowitz L
J Clin Pharmacol; 2001 Dec; 41(12):1319-28. PubMed ID: 11762559
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children.
Allegra S; Fatiguso G; De Francia S; Favata F; Pirro E; Carcieri C; De Nicolò A; Cusato J; Di Perri G; D'Avolio A
Clin Exp Pharmacol Physiol; 2017 Nov; 44(11):1083-1088. PubMed ID: 28744925
[TBL] [Abstract][Full Text] [Related]
10. Itraconazole (Sporanox) in superficial and systemic fungal infections.
Caputo R
Expert Rev Anti Infect Ther; 2003 Dec; 1(4):531-42. PubMed ID: 15482150
[TBL] [Abstract][Full Text] [Related]
11. Itraconazole.
Piérard GE; Arrese JE; Piérard-Franchimont C
Expert Opin Pharmacother; 2000 Jan; 1(2):287-304. PubMed ID: 11249550
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs.
Hasbach AE; Langlois DK; Rosser EJ; Papich MG
J Vet Intern Med; 2017 Jul; 31(4):1163-1169. PubMed ID: 28627123
[TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.
Zhou H; Goldman M; Wu J; Woestenborghs R; Hassell AE; Lee P; Baruch A; Pesco-Koplowitz L; Borum J; Wheat LJ
J Clin Pharmacol; 1998 Jul; 38(7):593-602. PubMed ID: 9702843
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.
Boogaerts MA; Maertens J; Van Der Geest R; Bosly A; Michaux JM; Van Hoof A; Cleeren M; Wostenborghs R; De Beule K
Antimicrob Agents Chemother; 2001 Mar; 45(3):981-5. PubMed ID: 11181397
[TBL] [Abstract][Full Text] [Related]
15. A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics.
Yi Y; Yoon HJ; Kim BO; Shim M; Kim SO; Hwang SJ; Seo MH
J Control Release; 2007 Jan; 117(1):59-67. PubMed ID: 17097755
[TBL] [Abstract][Full Text] [Related]
16. Optimisation of itraconazole therapy using target drug concentrations.
Poirier JM; Cheymol G
Clin Pharmacokinet; 1998 Dec; 35(6):461-73. PubMed ID: 9884817
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons.
Koks CH; Meenhorst PL; Bult A; Beijnen JH
Pharmacol Res; 2002 Aug; 46(2):195-201. PubMed ID: 12220961
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the bioavailability of itraconazole.
Grant EM
Conn Med; 2000 Jul; 64(7):415-7. PubMed ID: 10946480
[No Abstract] [Full Text] [Related]
19. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
20. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.
Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
Antimicrob Agents Chemother; 1998 Jul; 42(7):1862-5. PubMed ID: 9661037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
